10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
DBPR112 is an orally active furanopyrimidine-based EGFR inhibitor with IC 50 s of 15 nM and 48 nM for EGFR WT and EGFR L858R/T790M , respectively. DBPR112 can occupy the ATP-binding site. DBPR112 has significant antitumor efficacy
In Vitro
DBPR112 (compound 78; 0.32-1000 nM; 16 hours) induces reduction of phosphorylated EGFR in a dose-dependent manner. DBPR112 shows the inhibitory activity against HCC827 (CC 50 =25 nM), H1975 (CC 50 =620 nM) and A431 Cell (CC 50 =1.02 μM) cell lines. DBPR112 occupies the ATP-binding site and interacts with surrounding residues by covalent bonding, hydrogen bonds, and hydrophobic interactions, which give it a potent inhibitory activity against WT EGFR. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: H1975 cells Concentration: 0.32, 1.6, 8.0, 40, 200, 1000 nM Incubation Time: 16 hours Result: Induced reduction of phosphorylated EGFR in a dose-dependent manner in H1975 cells.
In Vivo
DBPR112 (orally; 20-50 mg/kg; 5 days/week for 2 consecutive weeks) significantly reduces tumor growth in HCC827 tumor model. DBPR112 (orally; 50 mg/kg; once a day for 15 days) has a significant antitumor effect (mean tumor growth inhibition of 34%) in H1975 tumor model . DBPR112 (IV; 5 mg/kg) has a T 1/2 of 2.3 hours, a CL of 55.6 mL/min•kg, and a V ss of 8.6 L/kg for rats . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: HCC827 tumor model (6- to 8-week-old athymic NU-Fox1nu nude mice) Dosage: 20, 50 mg/kg Administration: Orally; 5 days/week for 2 consecutive weeks (days 1-5 and 8-12) Result: Significantly reduced tumor growth. Animal Model: Rats Dosage: 5 mg/kg for IV and 20 mg/kg for PO (Pharmacokinetic Analysis) Administration: IV or PO Result: Had a T 1/2 of 2.3 hours, a CL of 55.6 mL/min•kg, and a V ss of 8.6 L/kg by IV. Had a T 1/2 of 3.4 hours, a C max of 508 ng/mL and an AUC of 2978 ng/mL•h by PO.
IC50& Target:EGFR WT 15 nM (IC 50 ) EGFR L858R/T790M 48 nM (IC 50 )
| Isomeric SMILES | CN(C)C/C=C/C(=O)NC1=CC=CC(=C1)C2=C(OC3=NC=NC(=C23)N[C@H](CO)C4=CC=CC=C4)C5=CC=CC=C5 |
|---|---|
| PubChem CID | 46212971 |
| Molecular Weight | 533.62 |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
